NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype

Apoptosis

Volumn 19, Issue 5, 2014, Pages 895-904

  Hong, Seung Woo ^a   Shin, Jae Sik ^a   Moon, Jai Hee ^a   Kim, Ye Seul ^a   Lee, Jooyoung ^a   Choi, Eun Kyoung ^a   Ha, Seung Hee ^a   Lee, Dae Hee ^a,c   Chung, Ha Na ^a   Kim, Jeong Eun ^a   Kim, Kyu Pyo ^a   Hong, Yong Sang ^a   Lee, Jae Lyun ^a   Lee, Wang Jae ^b   Choi, Eun Kyung ^a   Lee, Jung Shin ^a   Jin, Dong Hoon ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Apoptosis; Autophagy; NVP BEZ235; PTEN

Indexed keywords

CASPASE 3; COMPLEMENTARY DNA; DACTOLISIB; GAMMA TUBULIN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BID; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL STRAIN LNCAP; CELL VIABILITY; CELL VIABILITY ASSAY; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; GENOTYPE; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOBLOTTING; LIGHT CHAIN; MALE; NULL CELL; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; IMIDAZOLES; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; QUINOLINES; TOR SERINE-THREONINE KINASES;

EID: 84898843293     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-0973-4     Document Type: Article

References (27)

1. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261-1274. doi: 10.1016/j.cell.2007.06.009 (Pubitemid 46962095)
2. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678-7681. doi: 10.1158/0008-5472.CAN-04-2933 (Pubitemid 39446895)
3. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554. doi: 10.1126/science.10965021096502 (Pubitemid 38541907)
4. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH et al (2001) The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61(20):7426-7429 (Pubitemid 32995029)
5. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H et al (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106(52):22299-22304. doi: 10.1073/pnas.0905152106
6. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z et al (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16(1):64-67. doi: 10.1038/ng0597-64 (Pubitemid 27198157)
7. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606-619. doi: 10.1038/nrg1879 (Pubitemid 44100518)
8. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127-150. doi: 10.1146/annurev.pathol.4.110807.092311
9. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG et al (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57(22):4997-5000 (Pubitemid 27498107)
10. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE et al (1998) PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17(15):1979-1982. doi: 10.1038/sj.onc.1202119 (Pubitemid 28488466)
11. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H et al (2006) The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 208(5):699-707. doi: 10.1002/path.1929
12. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15(15):4799-4805. doi: 10.1158/1078-0432.CCR-08-0125
13. Yoshimoto M, Bayani J, Nuin PA, Silva NS, Cavalheiro S, Stavale JN et al (2006) Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America. Cancer Genet Cytogenet 170(1):40-47. doi: 10.1016/j.cancergencyto.2006.05.009 (Pubitemid 44332562)
14. Halvorsen OJ, Haukaas SA, Akslen LA (2003) Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9(4):1474-1479 (Pubitemid 36418404)
15. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851-1863. doi: 10.1158/1535-7163.MCT-08-0017
16. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D et al (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17(8):2373-2384. doi: 10.1158/1078-0432.CCR-10-2289
17. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM et al (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8(8):2204-2210. doi: 10.1158/1535-7163.MCT-09-0160
18. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19(21):5720-5728. doi: 10.1093/emboj/19.21. 5720
19. Hendil KB, Lauridsen AM, Seglen PO (1990) Both endocytic and endogenous protein degradation in fibroblasts is stimulated by serum/amino acid deprivation and inhibited by 3-methyladenine. Biochem J 272(3):577-581
20. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C et al (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106(1):268-273. doi: 10.1073/pnas.0810956106
21. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW (2011) Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17(20):6482-6489. doi: 10.1158/1078-0432.CCR-11-0933
22. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K et al (2012) Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 7(5):e37431. doi: 10.1371/journal.pone.0037431PONE-D-12-01860
23. Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6(10):e26343. doi: 10.1371/journal.pone.0026343PONE-D-11-10214
24. Bitting RL, Armstrong AJ (2013) Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20(3):R83-R99. doi: 10.1530/ERC-12-0394ERC-12-0394
25. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10(2):262-267. (Pubitemid 28174769)
26. Degtyarev M, De Maziere A, Orr C, Lin J, Lee BB, Tien JY et al (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183(1):101-116. doi: 10.1083/jcb.200801099
27. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS et al (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-175. (Pubitemid 351231180)